Galecto (GLTO) - הון עצמי של החברה

Galecto, Inc. (GLTO) is building a closed metabolism control system through unique patented developments, locking clients into its own protocols. The business relies on the creation of anti-cancer and anti-fibrosis drugs in US and European centers, where the metric value is 0.30. However, a shortage of funds and past failures in pulmonary tests are creating pressure, as confirmed by the current share price chart on GURU.Markets.

For Galecto, Inc. (GLTO), which focuses on developing fibrosis and cancer therapies without current profits, external financing and the success of clinical trials are critical. By analyzing the trend in balance sheet capitalization, an investor assesses the difference between assets and liabilities, allowing them to track how operating expenses and cost inflation deplete the net asset value and impact overall capital stability.